According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are $1.15 Billion USD. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2024-12-31 | $1.12 B | 10.75% |
2023-12-31 | $1.01 B | 54.24% |
2022-12-31 | $0.66 B | -5.38% |
2021-12-31 | $0.69 B | 14.79% |
2020-12-31 | $0.60 B | -9.06% |
2019-12-31 | $0.66 B | 30.59% |
2018-12-31 | $0.51 B | 15.03% |
2017-12-31 | $0.44 B | 787.2% |
2016-12-31 | $50.2 M | -0.24% |
2015-12-31 | $50.33 M | 46.59% |
2014-12-31 | $34.33 M | 0.2% |
2013-12-31 | $34.26 M | -17.64% |
2012-12-31 | $41.6 M | -46.85% |
2011-12-31 | $78.28 M | -37.41% |
2010-12-31 | $0.12 B | 87.06% |
2009-12-31 | $66.86 M | -17.87% |
2008-12-31 | $81.4 M | -48.46% |
2007-12-31 | $0.15 B | 110.72% |
2006-12-31 | $74.96 M | -19.41% |
2005-12-31 | $93.01 M | -25.82% |
2004-12-31 | $0.12 B | -23.47% |
2003-12-31 | $0.16 B | 287.45% |
2002-12-31 | $42.28 M | 17.6% |
2001-12-31 | $35.95 M |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
![]() Repligen
RGEN | $0.86 B | -24.77% | ๐บ๐ธ USA |
![]() Royalty Pharma RPRX | $7.81 B | 578.78% | ๐ฌ๐ง UK |
![]() Palatin Technologies PTN | $10.11 M | -99.12% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $73.54 B | 6,283.85% | ๐บ๐ธ USA |
![]() AbbVie ABBV | $134.70 B | 11,592.97% | ๐บ๐ธ USA |
![]() Pfizer PFE | $117.39 B | 10,090.19% | ๐บ๐ธ USA |
![]() ANI Pharmaceuticals ANIP | $0.84 B | -26.31% | ๐บ๐ธ USA |
![]() Athersys ATHX | $43.82 M | -96.20% | ๐บ๐ธ USA |